Disclosures for "Investigating the Relationship Between Oximetry Trends During Endovascular Therapy and Neurological Worsening for Patients with Acute Ischemic Stroke")
-
Miss Olexa has nothing to disclose.
-
Miss Begunova has nothing to disclose.
-
Mr. Bartolome has nothing to disclose.
-
Dr. Peng has nothing to disclose.
-
Charles Matouk has nothing to disclose.
-
Dr. Sheth has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Ceribell. Dr. Sheth has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Zoll. Dr. Sheth has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for NControl. Dr. Sheth has received stock or an ownership interest from Astrocyte. Dr. Sheth has received stock or an ownership interest from Alva. The institution of Dr. Sheth has received research support from Biogen. The institution of Dr. Sheth has received research support from Novartis. The institution of Dr. Sheth has received research support from Bard. The institution of Dr. Sheth has received research support from Hyperfine. Dr. Sheth has received intellectual property interests from a discovery or technology relating to health care.
-
Dr. Petersen has received research support from NIH.